ISSN 2664-8059 (Print) & ISSN 2706-767X (Online)
South Asian Research Journal of Nursing and Healthcare
Abbreviated Key Title: South Asian Res J Nurs Health Care

| Volume-7 | Issue-3 | May-Jun- 2025 | **DOI: https://doi.org/10.36346/sarjnhc.2025.v07i03.004**

Review Article

Pregnancy Weight Gain: New Research Reveals Hidden Risks of Maternal Obesity

Heimann N[1], Handzlik I[2*]

[1]District Hospital named after Prof. Roman Drews, Chodzież
[2]Dr. Jan Biziel University Hospital No. 2, Bydgoszcz

***Corresponding Author:** Handzlik I
Dr. Jan Biziel University Hospital No. 2, Bydgoszcz

Article History
Received: 17.04.2025
Accepted: 23.05.2025
Published: 17.06.2025

Abstract: The global prevalence of maternal obesity has increased dramatically, with approximately 39 million pregnancies annually complicated by maternal obesity. This review examines the multifaceted risks associated with excessive gestational weight gain and maternal obesity, exploring both established complications and emerging concerns through current research evidence. ***Methods*:** We conducted a comprehensive analysis of recent literature on maternal obesity, focusing on epidemiological trends, pathophysiological mechanisms, and clinical outcomes. The review synthesizes findings from systematic reviews, meta-analyses, and randomized controlled trials published primarily within the last decade to provide an evidence-based assessment of obesity-related pregnancy complications. ***Results*:** Maternal obesity demonstrates strong associations with numerous adverse outcomes, including fertility impairment, early pregnancy loss, hypertensive disorders, and gestational diabetes. For every 5 kg/m² increase in BMI above the ideal range, stillbirth risk increases by 24%. Obese women exhibit 3.69-fold higher risk of gestational hypertension and significantly elevated pre-eclampsia risk through mechanisms involving adiposopathy, insulin resistance, and complement system dysregulation. Labor complications include threefold higher odds of induction failure and cesarean rates reaching 52.3% in morbidly obese women. Importantly, maternal obesity programs lasting metabolic dysfunction in offspring, with effects detectable even at age 60. ***Conclusion*:** The evidence demonstrates that maternal obesity represents a significant modifiable risk factor affecting both immediate pregnancy outcomes and long-term health trajectories of mothers and offspring. While dietary interventions show greater efficacy than physical activity alone in managing gestational weight gain, intervention timing is critical, with implementation before 20 weeks' gestation yielding superior outcomes. These findings underscore the importance of preconception counseling and early pregnancy interventions to mitigate obesity-related pregnancy complications.

Keywords: Maternal Obesity, Gestational Weight Gain, Pregnancy Complications, Gestational Diabetes, Stillbirth.

INTRODUCTION

The patterns of gestational weight gain have undergone substantial transformation concurrent with the global obesity epidemic, presenting unprecedented challenges for maternal-fetal medicine practitioners. The worldwide prevalence of overweight and obesity during pregnancy continues to exhibit a dramatic upward trajectory, with approximately 39 million pregnancies annually complicated by maternal obesity [17]. Certain countries demonstrate particularly concerning rates, with maternal obesity reaching 64% in South Africa, 65% in Mexico, and 55-63% in the United States [17]. Of further significance, approximately 1 in 1000 births in the UK occur to women with a body mass index (BMI) exceeding 50 kg/m², indicating a troubling progression toward extreme obesity in pregnancy [17].

For women classified as overweight, the recommendations regarding gestational weight gain differ markedly from those applicable to women of normal weight. According to the Institute of Medicine guidelines, women with a BMI of 30 kg/m² or greater are advised to gain merely 5 to 9 kg throughout pregnancy [17]. Nevertheless, excessive gestational weight gain remains prevalent and contributes to numerous adverse outcomes. The World Health Organization has characterized

this rise in obesity as a "global epidemic," with overweight and obesity rates nearly tripling between 1975 and 2016 [16]. Consequently, maternal obesity has emerged as a significant public health concern with profound implications for both maternal and fetal wellbeing.

Overweight and obesity complicate up to two-thirds of pregnancies, markedly elevating the risk of gestational diabetes, hypertension, pre-eclampsia, and maternal and fetal mortality [17]. A systematic review determined that for every 5 kg/m² increase in BMI above the ideal range, the odds of stillbirth increased by 24% [17]. Furthermore, maternal obesity is associated with venous thromboembolism, with studies indicating that up to 57% of women who died from this condition during pregnancy were classified as obese [16]. The heightened incidence of congenital anomalies, including spina bifida and cardiac defects, further underscores the multifaceted risks associated with excessive gestational weight gain [16].

In our survey, we examine the most recent research on maternal obesity and pregnancy weight gain, exploring both established and emerging risks. We investigate the pathophysiological mechanisms underlying these complications, evaluate current weight management strategies, and discuss evidence-based interventions to optimize outcomes for mothers and their offspring.

Global Epidemiology of Maternal Obesity and Overweight

Maternal obesity constitutes a critical public health challenge with marked variation across global regions. The worldwide prevalence of maternal overweight and obesity exhibits a steady upward trajectory, presenting substantial challenges for obstetric care providers and health systems throughout the world.

Prevalence Trends in High-Income vs. Low-Income Countries

The global landscape of maternal obesity reveals distinct geographical patterns. In 2022, 43% of adults worldwide were overweight, with 16% living with obesity [17]. Though initially considered primarily a high-income country phenomenon, maternal overweight is increasingly prevalent in low- and middle-income countries (LMICs) [17]. In urban areas of Ghana, Kenya, Niger, Sierra Leone, Tanzania, and Zimbabwe, the prevalence among reproductive-age women approaches 50% [16]. Meanwhile, in urban Mauritania, over half of reproductive-aged women are currently overweight or obese [16].

The rate of increase in LMICs is particularly concerning. The annualized change in prevalence from approximately 2000 to 2010 among women in urban areas of Bangladesh, Ghana, Malawi, Nepal, Niger, Rwanda, Zambia, and Zimbabwe was at least 1.00% [16]. This suggests that if trends continue, the prevalence of overweight in these regions will increase by 10% over the next decade [16]. Moreover, while prevalence remains lower in rural areas of most LMICs compared with urban settings, the rate of increase in several countries, such as Burkina Faso, Kenya, Uganda, and Zimbabwe, is now greater in rural regions [16].

In high-income countries, maternal obesity rates remain elevated. A systematic review estimated that in the 2010-2019 decade, the global prevalence of maternal obesity was 16.3%, approximating one in six pregnancies [16]. Combined maternal overweight and obesity had a pooled prevalence of 43.8%, approaching half of all pregnancies [16].

BMI Distribution among Reproductive-Age Women

The distribution of BMI among reproductive-age women demonstrates concerning shifts toward higher values. Statistical analyses reveal a rightward shift in the BMI distribution curve over time, with mean BMI increasing from 22.4 kg/m² in 1998 to 23.9 kg/m² in 2016 [17]. Correspondingly, the proportion of women with normal BMI has steadily decreased, while percentages of overweight and obesity have risen [17].

The prevalence varies substantially by region, with North America showing the highest rates (obesity: 18.7%; overweight/obesity combined: 47.0%) and Asia demonstrating the lowest (obesity: 10.8%; overweight/obesity combined: 28.5%) [16]. Both maternal obesity and combined overweight/obesity prevalence increased annually by 0.34% and 0.64% respectively [16]. Linear regression models estimate current global prevalence of maternal obesity at 20.9% and project this will increase to 23.3% by 2030 [16].

Sociodemographic Risk Factors: Age, Ethnicity, and Deprivation

Multiple sociodemographic factors influence maternal obesity risk. Age represents a significant determinant, with studies consistently showing obesity rates increase with advancing maternal age [17]. In one study, obesity rates at age 30 and over increased 2.2 times compared to younger women [17].

Ethnicity plays a crucial role in obesity risk distribution. In the Netherlands, the prevalence of prepregnancy overweight and obesity was 23.1% among Dutch-origin women, whereas significantly higher prevalences were observed among Dutch Antillean-origin (40.8%), Moroccan-origin (49.9%), Surinamese-Creole-origin (38.6%), and Turkish-origin

(41.1%) women [8]. Similarly, in Spain, high incidences of overweight and obesity were recorded in pregnant women from Maghrebi, sub-Saharan African, and Latin American populations, with odds ratios of 4.08, 3.18, and 1.59, respectively [8].

Socioeconomic deprivation strongly correlates with maternal obesity risk. Women in the most deprived quintile had 60% higher odds of being obese compared to those in the least deprived quintile [17]. Educational level demonstrates an inverse relationship with obesity prevalence, with multivariate analysis showing that less than 8 years of schooling remained as the only demographic factor associated with obesity (RR 1.77) when compared to more than 12 years of education [17]. Likewise, household income exhibits a similar gradient, with the highest risk of overweight and obesity among women with income less than 2000 euros/month [17].

Impact of Obesity on Fertility and Assisted Reproduction

Female obesity profoundly disrupts reproductive function through multiple pathophysiological mechanisms, resulting in subfertility and diminished outcomes in assisted reproduction technologies. In the United States, 36.5% of women of reproductive age are obese [16], presenting considerable challenges for fertility specialists managing these patients.

Leptin Resistance and Ovulatory Dysfunction

Obesity-induced leptin resistance constitutes a central mechanism underlying ovulatory dysfunction. White adipose tissue secretes leptin, with circulating levels positively correlated with body fat mass [16]. In obesity, women develop hyperleptinemia and subsequent leptin resistance, creating a paradoxical state wherein the body becomes insensitive to this critical metabolic hormone [16]. This resistance impairs the hypothalamic-pituitary-ovarian axis communication, disrupting normal folliculogenesis and ovulation.

The pathophysiology involves a progressive establishment of leptin resistance, which occurs in distinct phases [16]. Initially, peripheral leptin sensitivity is maintained, followed by peripheral insensitivity with preserved central responsiveness, and finally complete central leptin resistance [16]. Of particular significance, this resistance appears organ-specific, with studies demonstrating that ovarian leptin resistance follows an initial increase in ovarian leptin signaling during early stages of diet-induced obesity [16].

Leptin resistance alters ovarian function through several discrete mechanisms. First, it modifies steroidogenesis, potentially inducing anovulation [16]. Second, it affects oocyte meiotic maturation, leading to compromised oocyte quality and embryo developmental competence [16]. Third, it disrupts glucose metabolism in ovarian tissue, as leptin signaling and glucose metabolism are intimately interconnected in oocytes [16]. The relative risk of anovulatory infertility is 2.7 (95% CI, 2.0-3.7) in women with BMI≥ 32 kg/m² at age 18 [16].

Obesity-Associated Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome affects between 6-10% of premenopausal women [16], and demonstrates strong association with obesity. Approximately 40-80% of women with PCOS are overweight or obese [16], and conversely, PCOS was 5-fold more common among unselected premenopausal overweight or obese women seeking weight loss advice compared to the general population (28.3% vs 5.5%) [16].

The relationship between obesity and PCOS involves complex bidirectional mechanisms. Obesity exacerbates numerous PCOS features through insulin resistance and hyperinsulinemia [17]. Compensatory hyperinsulinemia stimulates the intact MAP kinase pathway to enhance steroidogenesis, while insulin resistance in ovarian tissue leads to impaired metabolic signaling but intact steroidogenic activity [16]. This combination favours hyperandrogenemia and ovarian dysfunction [16].

Furthermore, obesity amplifies metabolic abnormalities in PCOS patients. Between 40% and 80% of women with PCOS demonstrate glucose intolerance, with women with PCOS and type 2 diabetes significantly more obese than their counterparts with normal glucose tolerance [16]. The conversion from impaired glucose tolerance to type 2 diabetes occurs at an accelerated rate, strongly dependent upon BMI [16].

Reduced IVF Success Rates in Obese Women

Assisted reproductive technologies consistently show inferior outcomes in obese women. Multiple studies confirm that obesity reduces clinical pregnancy rates and live birth rates while increasing miscarriage rates following in vitro fertilization (IVF) [17]. In women undergoing IVF treatment, a BMI ≥ 30 kg/m² corresponds with lower live birth rates in multiple studies [17].

Specifically, a meta-analysis demonstrated that each unit increase in BMI decreased the probability of implantation after assisted reproductive technologies by 2.2%-4.3% [17]. Remarkably, follicular fluid in obese women

contains higher levels of oleic acid, which can lead to embryo fragmentation [17]. Additionally, studies have found lower levels of n-3 polyunsaturated fatty acids in oocytes from obese women compared to normal-weight women [17].

Obese women require higher doses of follicle-stimulating hormone (FSH) for ovulation induction, with a weighted mean difference of 771 IU (95% CI, 700–842) compared to normal-weight women [16]. These women also face a higher risk of cycle cancelation [OR 1.86 (95% CI: 1.13–3.06)] and are less likely to ovulate [OR 0.44 (95% CI: 0.31–0.61)] [16]. Miscarriage risk is also elevated, with odds of miscarriage in women with BMI≥ 30 kg/m² being 1.53 (95% CI: 1.27-1.84) compared to women with BMI< 30 kg/m² [16].

Maternal Obesity and Risk of Early Pregnancy Loss

Obesity during gestation substantially escalates the risk of pregnancy loss throughout all trimesters, with diverse pathophysiological mechanisms implicated in these adverse outcomes. Comprehensive research demonstrates a dose-dependent relationship between elevated maternal BMI and early pregnancy failure, stillbirth, and maternal mortality.

BMI-Related Risk of First Trimester Miscarriage

The correlation between obesity and first trimester pregnancy loss is firmly established in the medical literature. Women with obesity (BMI ≥30 kg/m²) experience a 20% higher risk of early miscarriage compared to normal-weight women [17]. More concerning, obese women demonstrate 3.5 times increased risk of recurrent early miscarriage compared to normal-weight controls (95% CI 1.03-12.01) [17]. This association maintains consistency across both natural and assisted conception scenarios, with meta-analysis data indicating that women with BMI ≥25 kg/m² have 67% higher odds of miscarriage regardless of conception method (OR 1.67, 95% CI 1.25-2.25) [8].

In a prospective cohort study, women with overweight (OR 1.49, 95% CI 1.12-1.98) and obesity (OR 1.44, 95% CI 1.00-2.08) exhibited significantly higher odds of miscarriage compared to women of normal weight [8]. For women undergoing assisted reproductive technologies, the risk escalates further—obese women demonstrate 40% higher risk of miscarriage (RR 1.40, 95% CI 1.17-1.68) after adjusting for baseline covariates [17]. Furthermore, each one-unit increase in BMI correlates with a 3% higher miscarriage risk (RR 1.03, 95% CI 1.02-1.04) [17].

Stillbirth Risk and Gestational Weight Gain Interaction

The relationship between gestational weight gain (GWG), pre-pregnancy BMI, and stillbirth manifests complex interactions. Analysis of 2,230,310 births revealed that both inadequate weight gain and weight loss increase stillbirth risk across most BMI classes [16]. The highest risk appears after 36 completed weeks gestation, with dramatically elevated hazard ratios in women experiencing weight loss: normal weight (HR 18.85, 95% CI 8.25-43.09), overweight (HR 5.87, 95% CI 2.99-11.55), and obese (HR 3.44, 95% CI 2.34-5.05) [16].

Paradoxically, weight loss demonstrates protective effects against stillbirth in morbidly obese women between 24-28 weeks gestation (HR 0.56, 95% CI 0.34-0.95) [16]. Conversely, excess weight gain increases stillbirth risk in obese and morbidly obese women after 36 weeks (HR 2.00, 95% CI 1.55-2.58 and HR 3.16, 95% CI 2.17-4.62, respectively) [16]. Nonetheless, excess weight gain appears protective against stillbirth in normal-weight women between 24-28 weeks (HR 0.57, 95% CI 0.44-0.70) [16].

Maternal Mortality and Cardiovascular Complications

Maternal obesity significantly increases mortality risk during pregnancy and the postpartum period. Compared to normal-BMI women, the adjusted odds ratio for maternal death progressively increases with BMI category: overweight women (25-29.9 kg/m²) at 1.65 (95% CI 1.24-2.19), class I obesity (30-34.9 kg/m²) at 2.22 (95% CI 1.55-3.19), and class II-III obesity (≥35 kg/m²) at 3.40 (95% CI 2.17-5.33) [17].

Cardiovascular disease represents the predominant cause of death in obese pregnant women, with risk of maternal mortality from cardiovascular causes four times higher than in non-obese women [17]. Similarly, mortality from thromboembolism, hypertensive complications, and stroke is nearly tripled [17]. For women with pre-existing cardiac disease, obesity increases the risk of cardiac events during pregnancy by 70% (OR 1.7, 95% CI 1.0-2.7) [17].

Longitudinal studies with median follow-up of 73 years demonstrate that obesity during pregnancy is associated with increased risk of premature death and cardiovascular disease in later life [8]. Pregnancy-related complications, particularly in overweight women, function as "nature's stress test," potentially revealing underlying cardiovascular vulnerability [8]. Therefore, aggressive risk stratification before or early in pregnancy, coupled with cardio-obstetric co-management, constitutes a crucial intervention for these high-risk pregnancies [17].

Pregnancy Weight Gain: Elucidating the Concealed Risks of Maternal Obesity

Hypertensive Disorders and Pre-eclampsia in Obese Pregnancies

Hypertensive disorders complicate 5-10% of all pregnancies, with pre-eclampsia occurring in 2-8% of gestations worldwide [16]. The correlation between elevated body mass index (BMI) and hypertensive complications in pregnancy represents one of the most robust associations in obstetric medicine, with profound implications for maternal-fetal outcomes.

BMI as a Predictor of Gestational Hypertension

Pre-pregnancy BMI decisively determines blood pressure levels throughout gestation. Each 1 kg/m² increase in pre-pregnancy BMI corresponds to 0.25 mmHg higher systolic blood pressure (SBP) and 0.18 mmHg higher diastolic blood pressure (DBP) during pregnancy [17]. Every unit increase in maternal BMI is associated with 6% higher odds for gestational hypertension (adjusted OR 1.06; 95% CI 1.03-1.09) and 9% increased risk for pre-eclampsia (adjusted OR 1.09; 95% CI 1.04-1.14) [17].

The relationship between BMI and hypertensive disorders follows a non-linear pattern with a critical threshold. The risk of gestational hypertension decreases until a turning point of BMI=26.8 kg/m², after which each one-unit increment in maternal BMI increases risk by 16.4% [8]. Overweight women demonstrate 1.77-fold higher risk (95% CI 1.41-2.20) of gestational hypertension, yet obese women face substantially greater risk at 3.69-fold (95% CI 2.77-4.91) [8].

In our survey of postpartum outcomes, we found that women with BMI≥30 kg/m² at one-year postpartum demonstrate 85% higher likelihood of persistent hypertension following hypertensive disorders of pregnancy compared to normal-weight counterparts [18].

Pathophysiology of Pre-eclampsia in Obesity

The pathophysiological mechanisms linking obesity to pre-eclampsia involve multiple interconnected pathways. Primarily, obesity creates a state of profound dysfunction in adipose tissue—termed adiposopathy—characterized by dysregulation of immunological and hormonal systems [19]. This state produces critical metabolic alterations, including hyperleptinemia, hypoadiponectinemia, dyslipidemia, and insulin resistance [19].

Subsequently, hyperinsulinemia and insulin resistance act as central mechanisms linking obesity to pre-eclampsia [20]. These conditions precede clinical manifestations of pre-eclampsia, with studies showing that increased insulin levels toward pregnancy's end elevate blood pressure in experimental models [20]. Thus, the low-grade systemic inflammation present in obesity directly contributes to endothelial dysfunction—the fundamental pathophysiological process in pre-eclampsia development [20].

The complement system provides another critical link between adiposity and pre-eclampsia risk [10]. Complement components increase proportionally with obesity and correlate with BMI and adipose tissue distribution [10]. Among pregnant women, those with elevated serum concentrations of complement fragments Bb and C3a combined with obesity face the highest pre-eclampsia risk compared to those with either condition alone [10].

In obese individuals, leptin metabolism particularly affects pre-eclampsia development. High leptin levels reduce cytotrophoblast proliferation—a fundamental pathophysiological mechanism of pre-eclampsia—and simultaneously increase blood pressure and placental factors [9]. This coincides with reduced nitric oxide production, affecting endothelial integrity essential for uterine artery remodeling and hemodynamic adaptations in pregnancy [9].

PE Recurrence and Genetic Susceptibility

Pre-eclampsia demonstrates significant recurrence patterns strongly influenced by BMI. Women with obesity show 3.1-fold greater risk of recurrent pre-eclampsia (95% CI 1.5-6.7) compared to normal-weight women [16]. Even women with overweight status demonstrate 3.0-fold increased recurrence risk (95% CI 1.4-6.6) [16]. Furthermore, women developing hypertension between pregnancies face substantially higher risk of both incident pre-eclampsia (RR 6.1, 95% CI 2.9-13) and recurrent pre-eclampsia (RR 2.4, 95% CI 1.5-3.9) [16].

Genetic studies have identified specific variants contributing to pre-eclampsia susceptibility. Researchers have pinpointed DNA variants in ZNF831 and FTO genes as pre-eclampsia risk factors [2]. Interestingly, these same genes were previously associated with blood pressure regulation, and the FTO variant specifically with body mass index [2]. Additional blood pressure-related variants in MECOM, FGF5, and SH2B3 genes also associate with pre-eclampsia, increasing risk by 10-15% [2].

Genetic burden analysis confirms that an increasing load of risk alleles for elevated diastolic blood pressure and increased BMI correlates with heightened pre-eclampsia risk (DBP OR 1.11, 95% CI 1.01-1.21; BMI OR 1.10, 95% CI

1.00-1.20) [21]. This genetic effect appears particularly pronounced in early-onset pre-eclampsia cases occurring before 34 weeks gestation (DBP OR 1.30, 95% CI 1.08-1.56) [21].

Gestational Diabetes Mellitus and Metabolic Dysregulation

Gestational diabetes mellitus (GDM) constitutes one of the most prevalent endocrine disorders in pregnancy, with incidence rates approaching approximately 20% of all gestations globally [22]. This increasing prevalence correlates directly with the worldwide obesity epidemic among reproductive-age women.

Insulin Resistance in Pregnancy and Obesity

Normal pregnancy physiologically induces a 50-60% reduction in insulin sensitivity as gestation advances [1]. This alteration is most appropriately characterized as a post-receptor defect, manifesting in diminished capacity of insulin to mobilize GLUT4 transporters from intracellular compartments to cell surfaces [1]. Women with obesity exhibit 50-60% greater insulin resistance both in early pregnancy (~16 weeks) and in later gestation (28 weeks) when compared with normal-weight women [23]. Overweight individuals (≥95 kg) demonstrate threefold higher likelihood of developing severe insulin resistance than their lean/normal weight counterparts [24]. This pre-existing insulin resistance, when superimposed upon pregnancy-induced metabolic changes, creates a physiological environment wherein pancreatic β-cells cannot provide adequate compensation [25]. Although the percentage decrease in insulin sensitivity during pregnancy is similar across weight categories, obese women commence pregnancy from a substantially compromised metabolic baseline [1].

Macrosomia and Neonatal Complications

Maternal hyperglycemia precipitates fetal hyperinsulinemia, ultimately resulting in macrosomia—defined as birth weight exceeding 4,000g [25]. This complication affects between 15-45% of neonates born to mothers with GDM pregnancies [22], thereby imposing substantial risks for both mother and infant. In macrosomic deliveries, research demonstrates a 10-fold elevated risk of shoulder dystocia, 20-fold increased risk of severe shoulder dystocia, and 30-fold greater risks of obstetric brachial plexus injury and birth fractures [26]. Maternal complications encompass 3-fold higher risk of cesarean delivery for failure to progress and 2.5-fold increased risk of severe postpartum hemorrhage [26]. Furthermore, excessive gestational weight gain was associated with increased odds of delivering large-for-gestational-age infants (aOR 1.84, 95% CI 1.63-2.08) and macrosomia (aOR 1.78, 95% CI 1.55-2.04) [27].

GDM Risk Stratification by BMI and GWG

Pre-pregnancy BMI provides essential risk stratification for GDM development. Notably, 55.6% of GDM diagnoses occur in women with overweight or obesity status [7]. Gestational weight gain patterns significantly modify this baseline risk. Weight gain z-scores above average increased GDM risk among normal weight, overweight, and obese class I-II women, but not among those with class III obesity [3]. For overweight women with excessive weight gain, the adjusted odds ratio for GDM nearly doubled (aOR 1.98, 95% CI 1.36-2.87) [3]. Conversely, gestational weight gain below recommendations demonstrated a protective effect against GDM in women with class III obesity [3]. Early pregnancy gestational weight gain below average was particularly beneficial for all obese classes [3], suggesting potential value in targeted weight management interventions for high-risk women.

Labor and Delivery Complications in Obese Women

Maternal obesity profoundly disrupts the normal physiological processes of labor, introducing both mechanical and metabolic impediments during parturition. Comprehensive research establishes clear correlations between increasing body mass index (BMI) and adverse labor outcomes.

Uterine Dysfunction and Failed Induction

Obesity compromises myometrial contractility through several interrelated mechanisms. Disrupted endocrine factors, particularly elevated leptin and cholesterol concentrations, inhibit calcium influx into the myometrium, thereby antagonizing oxytocin action and diminishing uterine contractile capacity [28]. Obese primiparous women with unfavorable cervical conditions experience significantly extended labor durations—prolonged by 3.6 hours compared to non-obese counterparts—even after adjustment for potential confounding variables [29]. Failed induction rates reach 14.4% among obese women versus merely 5.1% in normal-weight women, representing nearly threefold higher odds (adjusted OR 2.96; 95% CI: 1.15-8.17) [30]. Of particular significance, implementation of standardized induction protocols demonstrates minimal efficacy in reducing cesarean rates among obese women, suggesting underlying physiological rather than practice-pattern explanations [31].

Increased Cesarean Section and Operative Delivery Rates

The probability of cesarean delivery shows a stepwise progression with increasing maternal BMI. Each unit increase of 1-kg/m² in BMI corresponds to 5% heightened cesarean risk among nulliparous patients [31]. Overall cesarean rates attain 43.9% in overweight/obese women compared with 29.3% in normal-weight counterparts [6]. For women with morbid obesity (BMI ≥40 kg/m²), cesarean rates escalate to 52.3% compared to 25.1% in normal-weight women [11].

Consequently, intraoperative intervals increase proportionally with BMI—median incision-to-delivery times for morbidly obese women extend to 12.0 minutes versus 9.0 minutes for normal BMI, with 20% of morbidly obese women experiencing intervals exceeding 18 minutes [32]. These delays persist after controlling for prior cesarean history (OR 2.81, 95% CI 2.24–3.56) [32]. Beyond failed induction, non-reassuring fetal status constitutes the predominant indication for cesarean delivery across all obesity classes [31].

Postpartum Hemorrhage and Surgical Risk

Obesity independently elevates hemorrhage-related morbidity. Women with BMI 30-39.9 kg/m² demonstrate 19% higher risk of composite hemorrhagic outcomes (aRR 1.19, 95% CI 1.08-1.31), primarily attributable to blood loss exceeding 1000mL (aRR 1.45, 95% CI 1.19-1.75) [33]. Similarly, obese women experience quantifiably greater blood loss (1,313 vs. 1,056 mL) and require more units when transfused (2.2 vs. 2.0 units) [34]. Throughout peripartum care, obesity increases the likelihood of hemorrhage-related severe morbidity (34.1% vs. 25%) and multiple morbidity indicators (17.1% vs. 7.9%) [34]. For overweight women, postpartum hemorrhage risk increases by 43% (adjusted OR 1.43; 95% CI 1.13-1.81), while class II-III obesity more than doubles this risk (adjusted OR 2.20; 95% CI 1.29-3.78) [35].

Long-Term Offspring Outcomes from Maternal Obesity

The transgenerational consequences of maternal obesity extend substantially beyond immediate birth complications, establishing persistent metabolic imprints that influence offspring health trajectories. Developmental programming introduces enduring physiological alterations manifesting throughout the lifespan of children born to obese mothers.

Fetal Programming and Adult-Onset Obesity

The developmental origin of health and disease concept establishes that disease risk derives not exclusively from genetic predisposition and adult lifestyle factors, but also from early developmental exposures [14]. Maternal obesity during gestation permanently modifies metabolic control processes in offspring, particularly affecting hypothalamic leptin responsiveness and subsequent appetite regulation [36]. Elevated maternal pre-pregnancy BMI consistently correlates with increased childhood adiposity and adverse body fat distribution [36]. Longitudinal investigations demonstrate that higher maternal pre-pregnancy BMI is associated with elevated offspring BMI at age 30 [36] and persists remarkably even at age 60 years [36]. Children of overweight and obese women face substantially increased risk of being born large-for-gestational age and subsequently developing overweight or obesity in childhood or adulthood [37]. Studies examining siblings born before and after maternal bariatric surgery provide compelling human evidence that differential intrauterine environments program varying cardiovascular risk profiles—those born following maternal weight loss demonstrate markedly reduced cardiovascular risk compared to siblings born during maternal obesity [38].

Type 2 Diabetes and Cardiovascular Risk in Offspring

Maternal obesity predisposes offspring to significant cardiometabolic vulnerabilities. Children exposed to maternal obesity exhibit structural cardiac alterations, including left ventricular hypertrophy and increased epicardial adiposity, with associated diastolic dysfunction evident by 12 months of age [38]. Furthermore, maternal obesity increases offspring hospitalization rates for cardiovascular events between ages 31-64 years [38]. The pathophysiological mechanism involves fetal adaptations to excessive nutrient exposure, including alterations in gene expression, cellular metabolism, and epigenetic modifications [15]. Obesity-associated gestational diabetes increases glucose and fatty acid supply to the developing fetus, programming lasting metabolic dysfunction [15]. Research documents heightened insulin resistance among offspring of obese mothers by their early twenties [5]. Notably, obesity-prone offspring from obese mothers display elevated leptin gene expression, hyperleptinemia, and adipocyte hypertrophy in white adipose tissue, maintained through epigenetic mechanisms including DNA hydroxymethylation and active histone marks [14].

Pregnancy Weight Gain: Elucidating the Concealed Risks of Maternal Obesity

!Hero Image for Pregnancy Weight Gain: New Research Reveals Hidden Risks of Maternal Obesity.

The patterns of gestational weight gain have undergone substantial transformation concurrent with the global obesity epidemic, presenting unprecedented challenges for maternal-fetal medicine practitioners. The worldwide prevalence of overweight and obesity during pregnancy continues to exhibit a dramatic upward trajectory, with approximately 39 million pregnancies annually complicated by maternal obesity. Certain countries demonstrate particularly concerning rates, with maternal obesity reaching 64% in South Africa, 65% in Mexico, and 55-63% in the United States. Of further significance, approximately 1 in 1000 births in the UK occur to women with a body mass index (BMI) exceeding 50 kg/m², indicating a troubling progression toward extreme obesity in pregnancy.

For women classified as overweight, the recommendations regarding gestational weight gain differ markedly from those applicable to women of normal weight. According to the Institute of Medicine guidelines, women with a BMI of 30 kg/m² or greater are advised to gain merely 5 to 9 kg throughout pregnancy. Nevertheless, excessive gestational weight

gain remains prevalent and contributes to numerous adverse outcomes. The World Health Organization has characterized this rise in obesity as a "global epidemic," with overweight and obesity rates nearly tripling between 1975 and 2016. Consequently, maternal obesity has emerged as a significant public health concern with profound implications for both maternal and fetal wellbeing.

Overweight and obesity complicate up to two-thirds of pregnancies, markedly elevating the risk of gestational diabetes, hypertension, pre-eclampsia, and maternal and fetal mortality. A systematic review determined that for every 5 kg/m² increase in BMI above the ideal range, the odds of stillbirth increased by 24%. Furthermore, maternal obesity is associated with venous thromboembolism, with studies indicating that up to 57% of women who died from this condition during pregnancy were classified as obese. The heightened incidence of congenital anomalies, including spina bifida and cardiac defects, further underscores the multifaceted risks associated with excessive gestational weight gain.

In our survey, we examine the most recent research on maternal obesity and pregnancy weight gain, exploring both established and emerging risks. We investigate the pathophysiological mechanisms underlying these complications, evaluate current weight management strategies, and discuss evidence-based interventions to optimize outcomes for mothers and their offspring.

Clinical Interventions and Evidence-Based Strategies

Effective management strategies for maternal obesity represent a critical frontier in obstetric medicine, wherein intervention efficacy demonstrates substantial variation contingent upon modality, timing, and personalization. The exploration of these interventions yields insights into optimal approaches for mitigating obesity-related pregnancy risks.

Diet-Based vs. Physical Activity Interventions

Meta-analysis evidence indicates dietary interventions produce superior outcomes compared to physical activity alone in the management of gestational weight gain. Diet-based approaches yielded average gestational weight gain (GWG) reductions of 3.84 kg in contrast to the more modest 1.42 kg achieved with physical activity interventions [4]. Of particular significance, diet interventions demonstrated meaningful reductions in preeclampsia risk, albeit without corresponding decreases in cesarean delivery rates [39]. A systematic review of randomized controlled trials (RCTs) confirmed that interventions centered around dietary modification effectively control weight gain and reduce pregnancy complications [40]. Notably, when examining specific components of lifestyle interventions, non-theory-based approaches demonstrated greater GWG reduction (-1.37 kg) than theory-based programs (-0.74 kg; p=0.02) [13], suggesting that pragmatic approaches may yield superior outcomes in this population.

RCT Outcomes: LIMIT, UPBEAT, and Bumps & Beyond

The UK Pregnancies Better Eating and Activity Trial (UPBEAT) evaluated an intensive behavioral intervention combining dietary advice (emphasizing low glycemic index foods and reduced saturated fat intake) with structured physical activity recommendations [12]. Under these conditions, UPBEAT successfully reduced dietary glycemic load and achieved modest reductions in GWG, yet failed to demonstrate significant improvements in gestational diabetes mellitus (GDM) incidence or large-for-gestational-age (LGA) deliveries [12]. Economic analysis revealed concerning data regarding intervention sustainability, with cost-utility analysis estimating merely 1% probability of UPBEAT being cost-effective at the £30,000/quality-adjusted life-year threshold [12]. When analyzed collectively with other major RCTs, meta-analysis revealed that combined diet and physical activity interventions produced modest reductions in cesarean section rates (OR 0.91, 95% CI 0.83-0.99) [4]. The LIFE-Moms consortium reported comparable findings, demonstrating that multi-component interventions achieved 1.6 kg GWG reduction without corresponding improvements in adverse pregnancy outcomes [41].

Timing and Personalization of Antenatal Interventions

Intervention timing critically influences efficacy, with evidence indicating a narrow implementation window exists prior to 20 weeks' gestation [40]. This timing consideration reflects fundamental maternal physiological processes, as maternal weight gain accelerates approximately three to four times faster after 20 weeks compared to early pregnancy [40]. Among various intervention characteristics examined, allied health staff facilitation demonstrated significantly greater GWG reduction (-1.36 kg) compared to medical staff delivery (-0.85 kg; p<0.001) [16], suggesting that provider type may substantially influence intervention success. Interventions commencing in early pregnancy consistently demonstrated superior outcomes (-1.09 kg, 95% CI -1.35 to -0.83) [13]. To enumerate components associated with successful intervention, weekly evidence-based counseling with structured gestational weight monitoring demonstrated particular efficacy, with 21% lower gestational weight gain achieved in intervention groups compared to controls [42].

CONCLUSION

The evidence demonstrates that maternal obesity represents a significant modifiable risk factor affecting both immediate pregnancy outcomes and long-term health trajectories of mothers and offspring. While dietary interventions

show greater efficacy than physical activity alone in managing gestational weight gain, intervention timing is critical, with implementation before 20 weeks' gestation yielding superior outcomes. These findings underscore the importance of preconception counseling and early pregnancy interventions to mitigate obesity-related pregnancy complications.

REFERENCES

1. Catalano, P.M. and Shankar, K. (2017) 'Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child', BMJ, 356, j1.
2. McGinnis, R., Steinthorsdottir, V., Williams, N.O., Thorleifsson, G., Shooter, S., Hjartardottir, S., Bumpstead, S., Stefansdottir, L., Hildyard, L., Sigurdsson, J.K. et al. (2017) 'Variants in the fetal genome near FLT1 are associated with risk of preeclampsia', Nature Genetics, 49(8), pp. 1255-1260.
3. Goldstein, R.F., Abell, S.K., Ranasinha, S., Misso, M., Boyle, J.A., Black, M.H., Li, N., Hu, G., Corrado, F., Rode, L. et al. (2017) 'Association of gestational weight gain with maternal and infant outcomes: a systematic review and meta-analysis', JAMA, 317(21), pp. 2207-2225.
4. Thangaratinam, S., Rogozinska, E., Jolly, K., Glinkowski, S., Roseboom, T., Tomlinson, J.W., Kunz, R., Mol, B.W., Coomarasamy, A. and Khan, K.S. (2012) 'Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence', BMJ, 344, e2088.
5. Drake, A.J. and Reynolds, R.M. (2010) 'Impact of maternal obesity on offspring obesity and cardiometabolic disease risk', Reproduction, 140(3), pp. 387-398.
6. Sebire, N.J., Jolly, M., Harris, J.P., Wadsworth, J., Joffe, M., Beard, R.W., Regan, L. and Robinson, S. (2001) 'Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London', International Journal of Obesity, 25(8), pp. 1175-1182.
7. Hedderson, M.M., Gunderson, E.P. and Ferrara, A. (2010) 'Gestational weight gain and risk of gestational diabetes mellitus', Obstetrics and Gynecology, 115(3), pp. 597-604.
8. Poston, L., Caleyachetty, R., Cnattingius, S., Corvalán, C., Uauy, R., Herring, S. and Gillman, M.W. (2016) 'Preconceptional and maternal obesity: epidemiology and health consequences', The Lancet Diabetes & Endocrinology, 4(12), pp. 1025-1036.
9. Huda, S.S., Brodie, L.E. and Sattar, N. (2010) 'Obesity in pregnancy: prevalence and metabolic consequences', Seminars in Fetal and Neonatal Medicine, 15(2), pp. 70-76.
10. Lynch, A.M., Murphy, J.R., Gibbs, R.S., Levine, R.J., Giclas, P.C., Salmon, J.E. and Holers, V.M. (2010) 'The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia', BJOG: An International Journal of Obstetrics & Gynaecology, 117(4), pp. 456-462.
11. Cnattingius, S., Villamor, E., Johansson, S., Edstedt Bonamy, A.K., Persson, M., Wikström, A.K. and Granath, F. (2013) 'Maternal obesity and risk of preterm delivery', JAMA, 309(22), pp. 2362-2370.
12. Poston, L., Bell, R., Croker, H., Flynn, A.C., Godfrey, K.M., Goff, L., Hayes, L., Khazaezadeh, N., Nelson, S.M., Oteng-Ntim, E. et al. (2015) 'Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial', The Lancet Diabetes & Endocrinology, 3(10), pp. 767-777.
13. International Weight Management in Pregnancy (i-WIP) Collaborative Group (2017) 'Effect of diet and physical activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual participant data from randomised trials', BMJ, 358, j3119.
14. Zambrano, E., Nathanielsz, P.W. and Taylor, P.D. (2018) 'Maternal obesity in pregnancy developmentally programs adipose tissue inflammation in young, lean male mice offspring', Endocrinology, 159(12), pp. 3782-3798.
15. Reynolds, R.M., Allan, K.M., Raja, E.A., Bhattacharya, S., McNeill, G., Hannaford, P.C., Sarwar, N., Lee, A.J., Bhattacharya, S. and Norman, J.E. (2013) 'Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years', BMJ, 347, f4539.
16. Marchi, J., Berg, M., Dencker, A., Olander, E.K. and Begley, C. (2015) 'Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews', Obesity Reviews, 16(8), pp. 621-638.
17. Denison, F.C., Aedla, N.R., Keag, O., Hor, K., Reynolds, R.M., Milne, A. and Diamond, A. (2019) 'Care of women with obesity in pregnancy', BJOG: An International Journal of Obstetrics & Gynaecology, 126(3), pp. e62-e106.
18. Benschop, L., Duvekot, J.J., Versmissen, J., van Broekhoven, V., Steegers, E.A.P. and Roeters van Lennep, J.E. (2019) 'Blood pressure profile 1 year after severe preeclampsia', Hypertension, 73(1), pp. 176-183.
19. Leddy, M.A., Power, M.L. and Schulkin, J. (2008) 'The impact of maternal obesity on maternal and fetal health', Reviews in Obstetrics and Gynecology, 1(4), pp. 170-178.
20. Abbassi-Ghanavati, M., Greer, L.G. and Cunningham, F.G. (2009) 'Pregnancy and laboratory studies: a reference table for clinicians', Obstetrics and Gynecology, 114(6), pp. 1326-1331.
21. Cluver, C.A., Hannan, N.J., van Papendorp, E., Hiscock, R., Beard, S., Mol, B.W., Tong, S. and Walker, S.P. (2020) 'Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial', American Journal of Obstetrics and Gynecology, 222(6), pp. 616-626.
22. Plows, J.F., Stanley, J.L., Baker, P.N., Reynolds, C.M. and Vickers, M.H. (2018) 'The pathophysiology of gestational diabetes mellitus', International Journal of Molecular Sciences, 19(11), p. 3342.

23. Sivan, E., Chen, X., Homko, C.J., Reece, E.A. and Boden, G. (1997) 'Longitudinal study of carbohydrate metabolism in healthy obese pregnant women', Diabetes Care, 20(9), pp. 1470-1475.
24. Lappas, M., Yee, K., Permezel, M. and Rice, G.E. (2005) 'Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies', Journal of Endocrinology, 186(3), pp. 457-465.
25. Catalano, P.M., McIntyre, H.D., Cruickshank, J.K., McCance, D.R., Dyer, A.R., Metzger, B.E., Lowe, L.P., Trimble, E.R., Coustan, D.R., Hadden, D.R. et al. (2012) 'The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes', Diabetes Care, 35(4), pp. 780-786.
26. Zhang, C., Rawal, S. and Chong, Y.S. (2016) 'Risk factors for gestational diabetes: is prevention possible?', Diabetologia, 59(7), pp. 1385-1390.
27. Zheng, W., Huang, W., Zhang, L., Tian, Z., Li, J., Zhang, T., Han, T., Yan, K., Dong, X., Han, X. et al. (2021) 'Changes in gut microbiota composition and function in obese pregnant women and relationships with metabolic markers', FASEB Journal, 35(5), e21503.
28. Zhang, J., Bricker, L., Wray, S. and Quenby, S. (2007) 'Poor uterine contractility in obese women', BJOG: An International Journal of Obstetrics & Gynaecology, 114(3), pp. 343-348.
29. Norman, S.M., Tuuli, M.G., Odibo, A.O., Caughey, A.B., Roehl, K.A. and Cahill, A.G. (2012) 'The effects of obesity on the first stage of labor', Obstetrics and Gynecology, 120(1), pp. 130-135.
30. Wolfe, K.B., Rossi, R.A. and Warshak, C.R. (2011) 'The effect of maternal obesity on the rate of failed induction of labor', American Journal of Obstetrics and Gynecology, 205(2), pp. 128.e1-7.
31. Young, O.M., Twedt, R. and Catov, J.M. (2016) 'Pre-pregnancy maternal obesity and the risk of preterm preeclampsia in the American primigravida', Obesity, 24(6), pp. 1226-1229.
32. Gherman, R.B., Chauhan, S., Ouzounian, J.G., Lerner, H., Gonik, B. and Goodwin, T.M. (2006) 'Shoulder dystocia: the unpreventable obstetric emergency with empiric management guidelines', American Journal of Obstetrics and Gynecology, 195(3), pp. 657-672.
33. Butwick, A.J., Abreo, A., Bateman, B.T., Lee, H.C., El-Sayed, Y.Y., Stephansson, O. and Flood, P. (2018) 'Effect of maternal body mass index on postpartum hemorrhage', Anesthesiology, 128(4), pp. 774-783.
34. Blomberg, M. (2011) 'Maternal obesity and risk of postpartum hemorrhage', Obstetrics and Gynecology, 118(3), pp. 561-568.
35. Fyfe, E.M., Thompson, J.M., Anderson, N.H., Groom, K.M. and McCowan, L.M. (2012) 'Maternal obesity and postpartum haemorrhage after vaginal and caesarean delivery among nulliparous women at term: a retrospective cohort study', BMC Pregnancy and Childbirth, 12, p. 112.
36. Reynolds, R.M., Osmond, C., Phillips, D.I. and Godfrey, K.M. (2010) 'Maternal BMI, parity, and pregnancy weight gain: influences on offspring adiposity in young adulthood', The Journal of Clinical Endocrinology & Metabolism, 95(12), pp. 5365-5369.
37. Godfrey, K.M., Reynolds, R.M., Prescott, S.L., Nyirenda, M., Jaddoe, V.W., Eriksson, J.G. and Broekman, B.F. (2017) 'Influence of maternal obesity on the long-term health of offspring', The Lancet Diabetes & Endocrinology, 5(1), pp. 53-64.
38. Fraser, A., Tilling, K., Macdonald-Wallis, C., Sattar, N., Brion, M.J., Benfield, L., Ness, A., Deanfield, J., Hingorani, A., Nelson, S.M. et al. (2010) 'Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood', Circulation, 121(23), pp. 2557-2564.
39. Oteng-Ntim, E., Varma, R., Croker, H., Poston, L. and Doyle, P. (2012) 'Lifestyle interventions for overweight and obese pregnant women to improve pregnancy outcome: systematic review and meta-analysis', BMC Medicine, 10, p. 47.
40. Thangaratinam, S., Rogozinska, E., Jolly, K., Glinkowski, S., Duda, W., Borowiack, E., Roseboom, T., Tomlinson, J., Walczak, J., Kunz, R. et al. (2012) 'Interventions to reduce or prevent obesity in pregnant women: a systematic review', Health Technology Assessment, 16(31), pp. iii-iv, 1-191.
41. The International Weight Management in Pregnancy (i-WIP) Collaborative Group (2017) 'Effect of diet and physical activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual participant data from randomised trials', BMJ, 358, j3119.
42. Muktabhant, B., Lawrie, T.A., Lumbiganon, P. and Laopaiboon, M. (2015) 'Diet or exercise, or both, for preventing excessive weight gain in pregnancy', Cochrane Database of Systematic Reviews, (6), CD007145.